CD8A and cancer: In our previous work, we discovered an IL-32–dependent pathway of DC differentiation, and we showed that recombinant IL-32γ (here after referred to as IL-32) induces human DC maturation and activation of CD8+ T cells in vitro, suggesting its therapeutic potential in cancer (17).